Application of MIDD in Clinical Research of Antitumor Drugs.
10.3779/j.issn.1009-3419.2022.101.38
- Author:
Mengyang YU
1
;
Hongyun WANG
1
Author Information
1. Clinical Pharmacology Research Center, Peking Union Medical College Hospital,
Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Exposure-response relationship;
Model-informed drug development;
Osimertinib;
Pembrolizumab;
Population pharmacokinetics
- MeSH:
Antineoplastic Agents/therapeutic use*;
Drug Development;
Humans;
Lung Neoplasms
- From:
Chinese Journal of Lung Cancer
2022;25(7):487-492
- CountryChina
- Language:Chinese
-
Abstract:
The antitumor drug has become one of the focused areas in new drug research and development. Their clinical research generally consumes a long period of time, with high cost and high risk. Model-informed drug development (MIDD) integrates and quantitatively analyzes physiological, pharmacological, and disease progression information through modeling and simulation, which can reduce the cost of drug development and improve the efficiency of clinical research. In this essay, Osimertinib and Pembrolizumab are given as examples to illustrate the specific application of MIDD in different phases of clinical research, aiming to provide references for the application of MIDD to guide the clinical research of antitumor drugs.
.
